Evidence map›Paper›PMID 33596911›Full record

ArticleMicrobial cell factories2021

Multiple copies of the oxytetracycline gene cluster in selected Streptomyces rimosus strains can provide significantly increased titers.

Špela Pikl, Andrés Felipe Carrillo Rincón, Lucija Slemc, Dušan Goranovič, Martina Avbelj, Krešimir Gjuračić, Hilda Sucipto, Katja Stare, Špela Baebler, Martin Šala and 4 more

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Genomic Insights and Synthetic Biology Applications of Marine ActinomyceteInternational journal of molecular sciences · 2024
    Article
  4. Article
  5. A genetic tool to express long fungal biosynthetic genes.Fungal biology and biotechnology · 2023
    Article
  6. Modulating Complex Secondary Metabolism inFood technology and biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Špela PiklDepartment of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Andrés Felipe Carrillo RincónDepartment of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Lucija SlemcDepartment of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Dušan GoranovičAcies Bio, d.o.o, Tehnološki Park, Ljubljana, Slovenia.
Martina AvbeljDepartment of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Krešimir GjuračićAcies Bio, d.o.o, Tehnološki Park, Ljubljana, Slovenia.
Hilda SuciptoPharmazeutische Biotechnologie, Universität des Saarlandes, Saarbrücken, Germany.
Katja StareNational Institute of Biology, Večna pot 111, Ljubljana, Slovenia.
Špela BaeblerNational Institute of Biology, Večna pot 111, Ljubljana, Slovenia.
Martin ŠalaNational Institute of Chemistry, Hajdrihova 19, SI-1000, Ljubljana, Slovenia.
Meijin GuoState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, China.
Andriy LuzhetskyyPharmazeutische Biotechnologie, Universität des Saarlandes, Saarbrücken, Germany.
Hrvoje PetkovićDepartment of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia. hrvoje.petkovic@bf.uni-lj.si.
Vasilka MagdevskaAcies Bio, d.o.o, Tehnološki Park, Ljubljana, Slovenia. vasilka.magdevska@aciesbio.com.
University of Ljubljana · SIAcies Bio (Slovenia) · SINational Institute of Biology · SISaarland University · DEEast China University of Science and Technology · CNNational Institute of Chemistry · SI

Funding

ERA-Co Biotech, NISSION 031B0611AJavna Agencija za Raziskovalno Dejavnost RS P4-0116Javna Agencija za Raziskovalno Dejavnost RS P4-0165Javna Agencija za Raziskovalno Dejavnost RS Programska skupina P4-0116Ministrstvo za visoko šolstvo, znanost in tehnologijo ERACoBiotec No. C3330-18-2520013
6 · The paper itself

Abstract

backgroundNatural products are a valuable source of biologically active compounds that have applications in medicine and agriculture. One disadvantage with natural products is the slow, time-consuming strain improvement regimes that are necessary to ensure sufficient quantities of target compounds for commercial production. Although great efforts have been invested in strain selection methods, many of these technologies have not been improved in decades, which might pose a serious threat to the economic and industrial viability of such important bioprocesses.

resultsIn recent years, introduction of extra copies of an entire biosynthetic pathway that encodes a target product in a single microbial host has become a technically feasible approach. However, this often results in minor to moderate increases in target titers. Strain stability and process reproducibility are the other critical factors in the industrial setting. Industrial Streptomyces rimosus strains for production of oxytetracycline are one of the most economically efficient strains ever developed, and thus these represent a very good industrial case. To evaluate the applicability of amplification of an entire gene cluster in a single host strain, we developed and evaluated various gene tools to introduce multiple copies of the entire oxytetracycline gene cluster into three different Streptomyces rimosus strains: wild-type, and medium and high oxytetracycline-producing strains. We evaluated the production levels of these engineered S. rimosus strains with extra copies of the oxytetracycline gene cluster and their stability, and the oxytetracycline gene cluster expression profiles; we also identified the chromosomal integration sites.

conclusionsThis study shows that stable and reproducible increases in target secondary metabolite titers can be achieved in wild-type and in high oxytetracycline-producing strains, which always reflects the metabolic background of each independent S. rimosus strain. Although this approach is technically very demanding and requires systematic effort, when combined with modern strain selection methods, it might constitute a very valuable approach in industrial process development.

Indexed as

Multigene FamilyOxytetracyclineStreptomyces rimosusOxytetracyclineBiosynthesisBiosynthetic gene clusterOxytetracyclineStreptomyces rimosusΦC31

Identifiers

PMID33596911
PMCPMC7890619
OpenAlexW3129684594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.